Alpha 1-antitrypsin deficiency surgery

	Alpha 1-antitrypsin deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Alpha 1-antitrypsin deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Alpha 1-antitrypsin deficiency surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Alpha 1-antitrypsin deficiency surgery
CDC on Alpha 1-antitrypsin deficiency surgery
Alpha 1-antitrypsin deficiency surgery in the news
Blogs on Alpha 1-antitrypsin deficiency surgery
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Lung volume reduction surgery (LVRS) can help relieve dyspnea and improve exercise capacity in patients with emphysema. But there is not enough evidence of its effectiveness in AAT deficiency.
One study demonstrated that bilateral LVRS in AAT-deficient patients with emphysema can be beneficial but functional measurements except 6 min walk test, returned to baseline at 6–12 months. Although, LVRS was not recommended for management of AAT deficiency.